Dyne Therapeutics DYN
NASDAQ DYN
$24.28 -0.67 (-2.69%)
As of: Sep 4, 2026 · 3:59 PM EDT

Dyne Therapeutics (DYN) Net Income (2019 - 2026)

Dyne Therapeutics (DYN) posted quarterly Net Income of -$262.6 million for Q2 2026, down 140.54% year-over-year from $647.7 million in Q2 2025, and down 49.82% quarter-over-quarter from -$175.3 million in Q1 2026.

Analysis

Dyne Therapeutics (DYN) Net Income (2019 - 2026) Analysis & Trends

Dyne Therapeutics (DYN) has reported Net Income for 8 consecutive years, with -$262.6 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Net Income fell 140.54% year-over-year to -$262.6 million; the TTM figure through Jun 2026 stood at -$657.2 million (down 53.32% YoY), while the FY2025 annual figure was -$857.6 million, down 41.6% from the prior year.
  • Net Income retreated to -$262.6 million in Q2 2026 per DYN's latest filing, from -$175.3 million in the prior quarter.
  • Across five years, Net Income topped out at -$62.5 million in Q1 2022 and bottomed at -$262.6 million in Q2 2026.
  • Historically, Net Income has averaged -$131.2 million across 5 years, with a median of -$108.7 million in 2025.
  • Annual changes were most pronounced in 2022 — Net Income tumbled 193.23% — and 2025, when it jumped 56.35%.
  • Dyne Therapeutics' Net Income stood at -$152.4 million in 2022, then sank by 38.9% to -$211.7 million in 2023, then soared by 55.37% to -$94.5 million in 2024, then fell by 17.48% to -$111.0 million in 2025, then slumped by 136.53% to -$262.6 million in 2026.
  • Business Quant data shows DYN's Net Income at -$262.6 million in Q2 2026, -$175.3 million in Q1 2026, and -$111.0 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -644.37 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 81.49 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -13.27 Mn
10 Dyne Therapeutics 4.02 Bn 4.02 Bn - -173.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -173.87 Mn
Mar 31, 2026 -125.89 Mn
Dec 31, 2025 -108.47 Mn
Sep 30, 2025 -108.32 Mn
Jun 30, 2025 -109.26 Mn
Mar 31, 2025 -122.14 Mn
Dec 31, 2024 -89.52 Mn
Sep 30, 2024 -96.29 Mn
Jun 30, 2024 -72.07 Mn
Mar 31, 2024 -69.29 Mn
Dec 31, 2023 -65.94 Mn
Sep 30, 2023 -60.08 Mn
Jun 30, 2023 -66.59 Mn
Mar 31, 2023 -45.10 Mn
Dec 31, 2022 -38.80 Mn
Sep 30, 2022 -41.38 Mn
Jun 30, 2022 -52.98 Mn
Mar 31, 2022 -36.44 Mn
Dec 31, 2021 -51.78 Mn
Sep 30, 2021 -42.58 Mn